Please ensure Javascript is enabled for purposes of website accessibility

Will Steve Jobs Get the Madoff Treatment?

By Tim Beyers – Updated Apr 6, 2017 at 3:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The SEC investigates the iconic CEO's medical disclosures

So now Steve Jobs is sick and a crook? Apparently, the Securities and Exchange Commission thinks it's a possibility. Bloomberg reports that the SEC is investigating whether investors were misled by Jobs' health disclosures.

Say it ain't so. Not because I own shares of Apple (NASDAQ:AAPL), but because it would be a profound waste of precious SEC resources.

He's still innocent till proven guilty, right?
Fortune writer Philip Elmer-DeWitt, a longtime Apple watcher, writes that the legal standard for proving Jobs and Apple guilty of wrongdoing is remarkably high. Regulators would have to show that Apple or Jobs (or both) intended to profit from selective disclosure.

Anything's possible, I suppose, but Jobs hardly sounds like someone bent on profiting from his health problems. "Why don't you guys leave me alone -- why is this important?" Jobs told Bloomberg in a phone interview last week, after specious reports surfaced that he might be subject to a liver transplant.

The difference between disclosure and deception
Readers could rightly point out that I've criticized Jobs for poor disclosure. I still believe that investors ought to have enough data to assess the chances of him retiring because of illness.

That we don't yet know more tells us only that Jobs is an intensely private man who doesn't wish to talk about the nature of his condition. I completely understand. But as I've written, Steve is more important to Apple than most other CEOs are to their firms. Certainly more than Dell's (NASDAQ:DELL) Michael Dell, IBM's (NYSE:IBM) Sam Palmisano, or Google's (NASDAQ:GOOG) Eric Schmidt. There's no escaping the need for some details -- but only enough for investors to make a fair assessment of risk.

So far, Jobs hasn't complied. That's certainly troubling, but I just can't see how it's a crime.

Dear SEC regulators, please spend your time on real stock market scandals, like the brouhaha over disappeared Florida manager Arthur Nadel, who has apparently made off with as much as $350 million of his clients' money. That's worth investigating. Jobs, not so much.

Get your clicks with related Foolishness:

  • Speculation began in earnest at the end of last year.
  • But we've been trying to kill Jobs for months.

Apple is a Stock Advisor selection. Google is a Rule Breakers recommendation. Dell is an Inside Value pick. Try any of these Foolish services free for 30 days. There's no obligation to subscribe.

Fool contributor Tim Beyers had stock and options positions in Apple and Google, and a stock position in IBM, at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy ordered bagels and coffee for lunch today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Apple Inc. Stock Quote
Apple Inc.
AAPL
$150.77 (0.23%) $0.34
Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$98.17 (-0.58%) $0.57
International Business Machines Corporation Stock Quote
International Business Machines Corporation
IBM
$122.01 (-0.57%) $0.70
Dell Technologies Inc. Stock Quote
Dell Technologies Inc.
DELL.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.